Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Medicine

Hackensack University Medical Center Foundation Receives Donation from Celgene to Advance Multiple Myeloma Research at John Theurer Cancer Center

Former Roche campus to be new Seton Hall-Hackensack Meridian School of Medicine

Hackensack, NJ, October 20, 2017 — The Hackensack University Medical Center Foundation announced on October 5 that it has received a substantial donation from Celgene Corporation to advance multiple myeloma research and transformational medicine that improve patient outcomes at Hackensack Meridian Health–John Theurer Cancer Center.

Supported by Celgene, a global biopharmaceutical leader in the discovery, development and delivery of treatment for diseases like multiple myeloma (MM), funds will help to establish the Multiple Myeloma Institute (MMI) — a leading-edge research facility at the Seton Hall-Hackensack Meridian School of Medicine scheduled to open in 2018.

Celgene and John Theurer Cancer Center are accomplished leaders in developing novel therapies for patients with multiple myeloma. Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, September 26, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, September 16, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading

Robert and Laura Garrett Gift $2.65 Million to Endow Seton Hall-Hackensack Meridian Med School Dean’s Post

Robert and Laura Garrett

Hackensack, NJ, August 3, 2017 — Anjalee Khemlani reports in NJBIZ that Hackensack Meridian Health co-CEO Robert Garrett and his wife, Laura Garrett, have provided a $2.65 million gift in honor of the new Seton Hall-Hackensack Meridian School of Medicine’s founding dean, Dr. Bonita Stanton.

Dr. Stanton was appointed to the Robert C. and Laura C. Garrett Endowed Chair for the School of Medicine Dean.

“Endowed chairs are among the highest honors conferred in academia, and the $15 million in support of endowments at Hackensack University Medical Center reinforces its role as one of the top-ranked academic medical centers in the country,” the health system said in a statement. Continue reading

U.N. Report: Over Half of People with HIV Having Treatment for First Time

London, July 31, 2017 — The Associated Press’ Maria Cheng reports that that, for the first time in the global AIDS epidemic that has spanned four decades and killed 35 million people, more than half of all those infected with HIV are on drugs to treat the virus, the United Nations said in a report released in Paris on July 20.

AIDS deaths are also now close to half of what they were in 2005, according to the U.N. AIDS agency, although those figures are based on estimates and not actual counts from countries.

Experts applauded the progress, but questioned if the billions spent in the past two decades should have brought more impressive results.  Continue reading

Opinion: NJAMHAA Mary Abrams Urges NJ’s Members of Congress to Reject GOP Interference with Medicare Part D

New Brunswick, NJ, July 13, 2017In a Star-Ledger opinion piece published on July 12, Mary Abrams, Senior Health Policy Analyst at the New Jersey Association of Mental Health and Addiction Agencies (NJAMHAA), writes:

Congress could soon weaken prescription drug coverage for more than 900,000 New Jersey residents.  Lawmakers want to fundamentally alter Medicare Part D, which has provided seniors and the disabled with affordable medicines for more than a decade.

The program has become a lifeline.  Without Part D, nearly two out of three seniors say that they would be unable to fill all of their prescriptions, while one in two say that they would be more likely to cut back or stop taking their medicines altogether. Continue reading

Seton Hall-Hackensack Meridian School of Medicine Dean Bonita Stanton Featured in ‘Industry Magazine’

Dr. Bonita Stanton

South Orange, NJ, June 21, 2017 — Dean Bonita Stanton, M.D., of the Seton Hall-Hackensack Meridian School of Medicine was interviewed and featured in the June 2017 issue of Industry Magazine.

The article, “Healthcare’s Horizon,” explores the new School of Medicine as a shift in paradigm for both medical pedagogy and health care delivery.

Noting how “The anticipated Seton Hall-Hackensack Meridian School of Medicine will offer an innovative team-based approach that will mirror how healthcare will be delivered in the future,” the article begins: Continue reading

Opinion: PhRMA CEO Stephen J. Ubl on ‘How to Negotiate Better Deals for Prescription Medicines’

Stephen J. Ubl

Washington, DC, June 6, 2017Pharmaceutical Research and Manufacturers of America (PhRMA) President and Chief Executive Officer Stephen J. Ubl writes in Forbes:

The way our health care system currently pays for prescription medicines is convoluted and confusing.  We rely on a complicated system of list prices, net prices, rebates and an opaque supply chain that often results in uncertainty and frustration for patients.

It is no wonder consumers and policymakers have questions and are looking for better answers. So are we. Continue reading

Biopharmaceutical Companies Unveil Latest GoBOLDLY TV Ad Showcasing ‘New World’ of Medicine

Washington, DC, May 17, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on May 15 unveiled its latest advertisement as part of its groundbreaking GOBOLDLY™ campaign, titled “New World, “featuring some of the most extraordinary breakthroughs in science being discovered by biopharmaceutical researchers.

“Biopharmaceutical researchers are driving unimaginable innovation in science, which is revolutionizing how the most complex diseases are treated,” said Stephen J. Ubl, president and chief executive officer of PhRMA.

“We truly are in a new world of medicine and on the verge of something even greater and more impactful. This promises a future with endless potential of scientific advances.” Continue reading

Non-Adherence: The Cost of Not Taking Your Medicine

New York, NY, April 21, 2017 — Jane E. Brody writes in her Well column in The New York Times that there is an out-of-control epidemic in the United States that costs more and affects more people than any disease Americans currently worry about. It’s called nonadherence to prescribed medications, and it is — potentially, at least — 100 percent preventable by the very individuals it afflicts.

The numbers are staggering. “Studies have consistently shown that 20 percent to 30 percent of medication prescriptions are never filled, and that approximately 50 percent of medications for chronic disease are not taken as prescribed,” according to a review in Annals of Internal Medicine. Continue reading